Magna Mining Announces Upgrade to OTCQX and Quarterly Results Conference Call & Webcast
2025 Quarterly Results Conference Call and Webcast
Magna Mining is scheduled to release their Q1 2025 financial results and MD&A after the market close on Thursday May 29, 2025. The company will be holding its first quarterly results conference call and webcast on Friday May 30, 2025 at 8:00 am EDT. The conference call details are as follows:
Webcast Link: https://www.gowebcasting.com/14081Participant Dial In: (N. America Toll Free): 1-844-763-8274Participant International Dial In: 1-647-484-8814
Conference call participants should ask to join the Magna Mining Inc. quarterly results conference call.
About Magna Mining Inc.
Magna Mining is a producing mining company with a portfolio of copper, nickel and PGM projects in the Sudbury Region of Ontario, Canada. The Company's primary assets are the producing McCreedy West copper mine and the past producing Levack, Podolsky, Shakespeare and Crean Hill mines. Additional information about the Company is available on SEDAR+ (www.sedarplus.ca) and on the Company's website (www.magnamining.com).
For further information, please contact:
Jason JessupChief Executive Officer
or
Paul Fowler, CFASenior Vice President705-482-9667Email: info@magnamining.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this press release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/253575
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
18 minutes ago
- Associated Press
Law Offices of Frank R. Cruz Encourages Lineage, Inc. (LINE) Investors to Inquire About Securities Fraud Class Action
LOS ANGELES--(BUSINESS WIRE)--Aug 11, 2025-- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of investors who purchased Lineage, Inc. ('Lineage' or the 'Company') (NASDAQ: LINE ) common stock pursuant and/or traceable to the registration statement used in connection with the Company's July 2024 initial public offering (the 'IPO'). Lineage investors have until September 30, 2025 to file a lead plaintiff motion. IF YOU SUFFERED A LOSS ON YOUR LINEAGE, INC. (LINE) INVESTMENTS, CLICKHERETO SUBMIT A CLAIM TO POTENTIALLY RECOVER YOUR LOSSES IN THE ONGOING SECURITIES FRAUD LAWSUIT. You can also contact the Law Offices of Frank R. Cruz to discuss your legal rights by email at [email protected], by telephone at (310) 914-5007, or visit our website at What Happened? In July 2024, Lineage conducted its IPO, selling over 65 million shares of common stock at $78 per share. On November 6, 2024, Lineage released its third quarter 2024 financial results, revealing that it had suffered a $543 million net loss during the quarter. On this news, Lineage's stock price fell $5.22, or 7.4%, to close at $65.79 per share on November 6, 2024, thereby injuring investors. Then, on January 14, 2025, The Wall Street Journal reported that Lineage was laying off employees due to reduced customer demand only six months after its IPO. Then, on April 7, 2025, Lineage announced the dismissal of its auditor, KPMG LLP. On this news, Lineage's stock price fell $5.29, or 9.9%, over two consecutive trading days, to close at $48.41 per share on April 8, 2025. Then, on April 30, 2025, Lineage reported first quarter 2025 financial results, including that '[t]otal revenue decreased (2.7)%' to $1.29 billion for the quarter. The Company stated it 'experienced more normal seasonal trends in the first quarter after multiple years of elevated inventory levels.' On this news, Lineage's stock price fell $8.16, or 14.62%, to close at $47.65 per share on April 30, 2025, thereby injuring investors further. On June 3, 2025, the Company stated at an Investor Conference that there has been 'pretty much flat demand' for Lineage's products and services and that the Company was operating in a 'flattish environment' in terms of demand. The price of Lineage stock has remained substantially below the IPO price at the time of this complaint's filing. What Is The Lawsuit About? The complaint filed in this class action alleges that the Registration Statement made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that Lineage was then experiencing sustained weakening in customer demand, as additional cold-storage supply had come on line, the Company's customers destocked a glut of excessive inventory built up during the COVID-19 pandemic, and the Company's customers shifted to maintaining leaner cold-storage inventories on a go-forward basis in response to changed consumer trends; (2) that Lineage had implemented price increases in the lead-up to the IPO that could not be sustained in light of the weakening demand environment facing the Company; (3) that Lineage was unable to effectively counteract the adverse trends listed in the foregoing through the use of minimum storage guarantees or as a result of operational efficiencies, technological improvements, or its purported competitive advantages; (4) that, as a result of the foregoing, rather than enjoying stable revenue growth, high occupancy rates, and steady rent escalation as represented in the Registration Statement, Lineage was in fact suffering from stagnant or falling revenue, occupancy rates, and rent prices; and (5) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. Contact Us To Participate or Learn More: If you purchased Lineage common stock, wish to learn more about this action, or have any questions concerning this announcement or your rights or interests with respect to these matters, please click HERE or contact us at: Law Offices of Frank R. Cruz 2121 Avenue of the Stars, Suite 800 Telephone: 310-914-5007 Email: [email protected] Visit our website at: This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. View source version on CONTACT: Law Offices of Frank R. Cruz 2121 Avenue of the Stars, Suite 800 Telephone: 310-914-5007 Email:[email protected] Visit our website at: KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: CLASS ACTION LAWSUIT PROFESSIONAL SERVICES LEGAL SOURCE: The Law Offices of Frank R. Cruz Copyright Business Wire 2025. PUB: 08/11/2025 12:06 PM/DISC: 08/11/2025 12:07 PM
Associated Press
18 minutes ago
- Associated Press
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Novo To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Novo between May 7, 2025, to July 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - August 11, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Novo Nordisk A/S ('Novo' or the 'Company') (NYSE: NVO) and reminds investors of the September 30, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. [ This image cannot be displayed. Please visit the source: ] Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose the true state of Novo's growth potential; notably, that its asserted potential to capitalize on the compounded market greatly understated the potential impact of the personalization exception to the compounded GLP-1 exclusion and overstated the likelihood such patients would switch to Novo's branded alternatives, and further greatly overstated the potential GLP-1 market or otherwise Novo's capability to penetrate said markets to achieve continued growth. On July 29, 2025, Novo announced it was lowering its sales and profit outlook ahead of reporting its results for the second quarter of fiscal year 2025. The Company attributed the guide down on 'lowered growth expectations for the second half of 2025" for both Wegovy and Ozempic due to 'the persistent use of compounded GLP-1s, slower-than-expected market expansion and competition.' Following this news, the price of Novo's common stock declined dramatically. From a closing market price of $69.00 per share on July 28, 2025, Novo's stock price fell to $53.94 per share on July 29, 2025, a decline of about 21.83% in the span of just a single day. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Novo's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Novo Nordisk class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. To view the source version of this press release, please visit
Business Wire
19 minutes ago
- Business Wire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals
NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rocket Pharmaceuticals, Inc. ('Rocket' or the 'Company') (NASDAQ: RCKT) and reminds investors of the August 11, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of RP-A501's safety and clinical trial protocol; notably, that Rocket knew Serious Adverse Events (SAEs), including death of participants enrolled in the study, were a risk. In particular, Rocket amended the trial's protocol to introduce a novel immunomodulatory agent to the pretreatment regimen without providing this critical update to shareholders. Such statements absent these material facts caused Plaintiff and other shareholders to purchase Rocket's securities at artificially inflated prices. On May 27, 2025, Rocket announced that the FDA placed a clinical hold on the RP-A501 Phase 2 pivotal study after at least one patient suffered a Serious Adverse Event (SAE), ultimately, death, while enrolled in the study following a substantive amendment to the protocol that the Company failed to disclose to investors at the time management made the revision. In fact, Rocket stated that, while the patient was dosed in May, the decision to amend the protocol was made 'several months' earlier. Despite this, Rocket made no attempt to alert investors or the public to the change until after the SAE occurred. Following this news, the price of Rocket's common stock declined dramatically. From a closing market price of $6.27 per share on May 23, 2025, Rocket's stock price fell to $2.33 per share on May 27, 2025, a decline of about 37% in the span of just a single trading day. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Rocket's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Rocket Pharmaceuticals class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
